Interferon-γ as an antifungal

Journal of Infectious Diseases

Volumn 194, Issue SUPPL. 1, 2006, Pages

  Stevens, David A ^a   Brummer, Elmer ^b   Clemons, Karl V ^b  

^a SANTA CLARA VALLEY MEDICAL CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CYTOKINE; GAMMA INTERFERON; INTERLEUKIN 12; MURAMYL DIPEPTIDE; TRANSFER FACTOR;

ADD ON THERAPY; ASPERGILLOSIS; CANDIDIASIS; CLINICAL TRIAL; CONFERENCE PAPER; CONGENITAL DISORDER; CRYPTOCOCCOSIS; DRUG MECHANISM; EFFECTOR CELL; GRANULOMATOSIS; HUMAN; IMMUNOTHERAPY; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; RESPIRATORY BURST;

ANTIFUNGAL AGENTS; HUMANS; INTERFERON TYPE II; MYCOSES;

EID: 33748863609     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/505357     Document Type: Conference Paper

References (102)

1. Merigan TC, Stevens DA, Rasmussen LE, Epstein LB. Interferon: an immune specific or a non-specific host defense? In: Braun W, Ungar J, eds. A re-examination of "non-specific" factors influencing host resistance. Basel: S. Karger, 1973:430-7.
2. Stevens DA. Interferon-gamma and fungal infections. In: Jaffe HS, Bucalo LR, Sherwin SA, eds. The anti-infective applications of interferon-gamma. New York: Marcel Dekker, 1992:279-91.
3. Wingard JR, Leather H. A new era of antifungal therapy. Biol Blood Marrow Transplant 2004; 10:73-90.
4. American Thoracic Society. Fungal infection in HIV-infected persons. Am J Respir Crit Care Med 1995; 152:816-22.
5. Chandrasekar PH, Alangaden G, Manavathu E. Aspergillus: an increasing problem in tertiary care hospitals? Clin Infect Dis 2000; 30:984-5.
6. Symoens F, Burnod J, Lebeau B, et al. Hospital-acquired Aspergillus fumigatus infection: can molecular typing methods identify an environmental source? J Hosp Infect 2002; 52:60-7.
7. Taylor GD, Buchanan-Chell M, Kirkland T, McKenzie M, Wiens R. Trends and sources of nosocomial fungaemia. Mycoses 1994; 37:187-90.
8. Uzun O, Ascioglu S, Anaissie EJ, Rex JH. Risk factors and predictors of outcome in patients with cancer and breakthrough candidemia. Clin Infect Dis 2001; 32:1713-7.
9. Walsh TJ, Hiemenz JW, Anaissie E. Recent progress and current problems in treatment of invasive fungal infections in neutropenic patients. Infect Dis Clin North Am 1996; 10:365-400.
10. Walsh TJ, Gonzalez C, Lyman CA, Chanock SJ, Pizzo PA. Invasive fungal infections in children: recent advances in diagnosis and treatment. Adv Pediatr Infect Dis 1996; 11:187-290.
11. Walsh TJ, Groll AH. Emerging fungal pathogens: evolving challenges to immunocompromised patients for the twenty-first century. Transpl Infect Dis 1999; 1:247-61.
12. Walsh TJ, Groll A, Hiemenz J, Fleming R, Roilides E, Anaissie E. Infections due to emerging and uncommon medically important fungal pathogens. Clin Microbiol Infect 2004; 10(Suppl 1):48-66.
13. Ponton J, Ruchel R, Clemons KV, et al. Emerging pathogens. Med Mycol 2000; 38(Suppl 1):225-36.
14. Beck-Sague C, Jarvis WR. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. J Infect Dis 1993; 167:1247-51.
15. McNeil MM, Nash SL, Hajjeh RA, et al. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997. Clin Infect Dis 2001; 33:641-7.
16. Clemons KV, Stevens DA. Overview of host defense mechanisms in systemic mycoses and the basis for immunotherapy. Semin Respir Infect 2001; 16:60-6.
17. Cox RA. Immunology of the fungal diseases. Boca Raton, FL: CRC Press, 1989.
18. Brummer E, Morozumi PA, Vo PT, Stevens DA. Protection against pulmonary blastomycosis: adoptive transfer with T lymphocytes, but not serum, from resistant mice. Cell Immunol 1982; 73:349-59.
19. Aly R, Berger T. Common superficial fungal infections in patients with AIDS. Clin Infect Dis 1996; 22(Suppl 2):S128-32.
20. Mitchell TG, Perfect JR. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 1995; 8:515-48.
21. Perfect JR, Schell WA, Rinaldi MG. Uncommon invasive fungal pathogens in the acquired immunodeficiency syndrome. J Med Vet Mycol 1993; 31:175-9.
22. Stevens DA. Fungal infections in AIDS patients. Br J Clin Pract Suppl 1990; 44(Suppl 71):11-22.
23. Stansell JD. Fungal disease in HIV-infected persons: cryptococcosis, histoplasmosis, and coccidioidomycosis. J Thorac Imaging 1991; 6:28-35.
24. Wheat J. Endemic mycoses in AIDS: a clinical review. Clin Microbiol Rev 1995; 8:146-59.
25. Stevens DA. Management of systemic manifestations of fungal disease in patients with AIDS. J Am Acad Dermatol 1994; 31:S64-7.
26. Denning DW, Ampel NM, Stevens DA. Opportunistic mycoses in HIV infection: aspergillosis and coccidioidomycosis. HIV Advances in Research and Therapy 1994; 4:22-9.
27. Lutz JE, Stevens DA, Sarosi GA. Coccidioidomycosis and HIV. HIV Newsline 1996; 2:17-23.
28. Morozumi PA, Brummer E, Stevens DA. Immunostimulation with muramyl dipeptide and its desmethyl analogue: studies of non-specific resistance to pulmonary blastomycosis in inbred mouse strains. Mycopathologia 1983; 81:35-9.
29. Brummer E, Stevens DA. Opposite modulation of lymph node cell and spleen cell responses to mitogens by muramyl dipeptide and its desmethyl analog. Cell Immunol 1981; 59:195-204.
30. Brummer E, Stevens DA. Mechanisms in opposite modulation of spleen cell and lymph node cell responses to mitogens following muramyl dipeptide treatment in vivo. Cell Immunol 1985; 91:505-14.
31. Schulking ML, Adler WH 3rd, Altemeier WA 3rd, Ayoub EM. Transfer factor in the treatment of a case of chronic mucocutaneous candidiasis. Cell Immunol 1972; 3:606-15.
32. Good RA. Transfer factor. Cell Immunol 1972; 3:i-iv.
33. Stevens DA. Transfer factor: treatment in coccidioidomycosis. In: Proceedings of the Third International Conference on the Mycoses. Washington, DC: Pan American Health Organization, 1975:72-7.
34. Stevens DA, Coccidioidomycosis Cooperative Treatment Group. Transfer factor therapy of infectious diseases. In: Frost P, Gomez EC, Zaias N, eds. Advances in dermatopharmacology. New York: Spectrum Publications, 1977:67-74.
35. Williams P, Brummer E, Stevens DA. Effect of prealbumin fraction with thymic hormone activity on the mononuclear cells of coccidioidomycosis patients and tuberculosis patients. In: Einstein HE, Cantanzaro A, eds. Coccidioidomycosis: proceedings of the Fourth International Conference. Washington, DC: National Foundation for Infectious Diseases, 1985:160-9.
36. Brummer E, Stevens DA. Macrophage colony-stimulating factor induction of enhanced macrophage anticryptococcal activity: synergy with fluconazole for killing. J Infect Dis 1994; 170:173-9.
37. Nassar F, Brummer E, Stevens DA. Effect of in vivo macrophage colony-stimulating factor on fungistasis of bronchoalveolar and peritoneal macrophages against Cryptococcus neoformans. Antimicrob Agents Chemother 1994; 38:2162-4.
38. Brummer E, Nassar F, Stevens DA. Effect of macrophage colony-stimulating factor on anticryptococcal activity of bronchoalveolar macrophages: synergy with fluconazole for killing. Antimicrob Agents Chemother 1994;38:2158-61.
39. Desai G, Nassar F, Brummer E, Stevens DA. Killing of Histoplasma capsulatum by macrophage colony stimulating factor-treated human monocyte-derived macrophages: role for reactive oxygen intermediates. J Med Microbiol 1995; 43:224-9.
40. Khemani S, Brummer E, Stevens DA. In vivo and in vitro effects of macrophage colony-stimulating factor (M-CSF) on bronchoalveolar macrophages for antihistoplasmal activity. Int J Immunopharmacol 1995; 17:49-53.
41. Nassar F, Brummer E, Stevens DA. Macrophage colony-stimulating factor (M-CSF) induction of enhanced anticryptococcal activity in human monocyte-derived macrophages: synergy with fluconazole for killing. Cell Immunol 1995; 164:113-8.
42. Natarajan U, Brummer E, Stevens DA. Effect of granulocyte colony-stimulating factor on the candidacidal activity of polymorphonuclear neutrophils and their collaboration with fluconazole. Antimicrob Agents Chemother 1997; 41:1575-8.
43. Natarajan U, Randhawa N, Brummer E, Stevens DA. Effect of granulocyte-macrophage colony-stimulating factor on candidacidal activity of neutrophils, monocytes or monocyte-derived macrophages and synergy with fluconazole. J Med Microbiol 1998; 47:359-63.
44. Vora S, Chauhan S, Brummer E, Stevens DA. Activity of voriconazole combined with neutrophils or monocytes against Aspergillus fumigatus: effects of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother 1998; 42:2299-303.
45. Brummer E, Maqbool A, Stevens DA. In vivo GM-CSF prevents dexamethasone suppression of killing of Aspergillus fumigatus conidia by bronchoalveolar macrophages. J Leukoc Biol 2001; 70:868-72.
46. Chiller T, Farrokhshad K, Brummer E, Stevens DA. Effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor on polymorphonuclear neutrophils, monocytes or monocyte-derived macrophages combined with voriconazole against Cryptococcus neoformans. Med Mycol 2002; 40:21-6.
47. Brummer E, Stevens DA. Effect of GM-CSF on antifungal activity of human phagocytes. In: Kawakami K, Stevens DA, eds. Immunomodulators as promising therapeutic agents against infectious diseases. Kerala, India: Research Signpost, 2004:13-21.
48. Brummer E, Morrison CJ, Stevens DA. Recombinant and natural gamma-interferon activation of macrophages in vitro: different dose requirements for induction of killing activity against phagocytizable and nonphagocytizable fungi. Infect Immun 1985; 49:724-30.
49. Brummer E, Hanson LH, Stevens DA. Gamma-interferon activation of macrophages for killing of Paracoccidioides brasiliensis and evidence for nonoxidative mechanisms. Int J Immunopharmacol 1988; 10:945-52.
50. Brummer E, Stevens DA. Candidacidal mechanisms of peritoneal macrophages activated with lymphokines or gamma-interferon. J Med Microbiol 1989; 28:173-81.
51. Brummer E, Stevens DA. Activation of pulmonary macrophages for fungicidal activity by gamma-interferon or lymphokines. Clin Exp Immunol 1987; 70:520-8.
52. Brummer E, Hanson LH, Restrepo A, Stevens DA. In vivo and in vitro activation of pulmonary macrophages by IFN-gamma for enhanced killing of Paracoccidioides brasiliensis or Blastomyces dermatitidis. J Immunol 1988; 140:2786-9.
53. Brummer E, Kurita N, Yoshida S, Nishimura K, Miyaji M. Killing of Histoplasma capsulatum by gamma-interferon-activated human monocyte-derived macrophages: evidence for a superoxide anion-dependent mechanism. J Med Microbiol 1991; 35:29-34.
54. Morrison CJ, Brummer E, Isenberg RA, Stevens DA. Activation of murine polymorphonuclear neutrophils for fungicidal activity by recombinant gamma interferon. J Leukoc Biol 1987; 41:434-40.
55. Morrison CJ, Stevens DA. Enhanced killing of Blastomyces dermatitidis by gamma interferon-activated murine peripheral blood polymorphonuclear neutrophils. Int J Immunopharmacol 1989; 11:855-62.
56. Morrison CJ, Brummer E, Stevens DA. In vivo activation of peripheral blood polymorphonuclear neutrophils by gamma interferon results in enhanced fungal killing. Infect Immun 1989; 57:2953-8.
57. Brummer E, Bhagavathula PR, Hanson LH, Stevens DA. Synergy of itraconazole with macrophages in killing Blastomyces dermatitidis. Antimicrob Agents Chemother 1992; 36:2487-92.
58. Brummer E, Stevens DA. Synergy of human neutrophils with fluconazole in killing Candida species. Mycopathologia 1996; 134:115-20.
59. Brummer E, Chauhan SD, Stevens DA. Collaboration of human phagocytes with LY 303366 for antifungal activity against Aspergillus fumigatus. J Antimicrob Chemother 1999; 43:491-6.
60. Garcha UK, Brummer E, Stevens DA. Synergy of fluconazole with macrophages for antifungal activity against Candida albicans. Mycopathologia 1995; 132:123-8.
61. Garcha UK, Brummer E, Stevens DA. Synergy of fluconazole with human monocytes or monocyte-derived macrophages for killing of Candida species. J Infect Dis 1995; 172:1620-3.
62. Stevens DA, Walsh TJ, Bistoni F, et al. Cytokines and mycoses. Med Mycol 1998; 36(Suppl 1):174-82.
63. Gujral S, Brummer E, Stevens DA. Role of extended culture time on synergy of fluconazole and human monocyte-derived macrophages in clearing Candida albicans. J Infect Dis 1996; 174:888-90.
64. Brummer E, Stevens DA. Synergy of azoles with macrophages in killing fungi. In: Vanden Bossche H, Stevens DA, Odds FC, eds. Host-fungus interplay. Bethesda, MD: National Foundation for Infectious Diseases, 1997:317-27.
65. Choi JH, Brummer E, Stevens DA. Combined action of micafungin, a new echinocandin, and human phagocytes for antifungal activity against Aspergillus fumigatus. Microbes Infect 2004; 6:383-9.
66. Chiller T, Farrokhshad K, Brummer E, Stevens DA. The interaction of human monocytes, monocyte-derived macrophages, and polymorphonuclear neutrophils with caspofungin (MK-0991), an echinocandin, for antifungal activity against Aspergillus fumigatus. Diagn Microbiol Infect Dis 2001; 39:99-103.
67. Vora S, Purimetla N, Brummer E, Stevens DA. Activity of voriconazole, a new triazole, combined with neutrophils or monocytes against Candida albicans: effect of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor. Antimicrob Agents Chemother 1998; 42:907-10.
68. Brummer E, Hanson LH, Stevens DA. IL-4, IgE, and interferon-gamma production in pulmonary blastomycosis: comparison in mice untreated, immunized, or treated with an antifungal (SCH 39304). Cell Immunol 1993; 149:258-67.
69. Hostetler JS, Brummer E, Coffman RL, Stevens DA. Effect of anti-IL-4, interferon-gamma and an antifungal triazole (SCH 42427) in paracoccidioidomycosis: correlation of IgE levels with outcome. Clin Exp Immunol 1993; 94:11-6.
70. Maffei CM, Mirels LF, Sobel RA, Clemons KV, Stevens DA. Cytokine and inducible nitric oxide synthase mRNA expression during experimental murine cryptococcal meningoencephalitis. Infect Immun 2004; 72:2338-49.
71. Joly V, Saint-Julien L, Carbon C, Yeni P. In vivo activity of interferon-gamma in combination with amphotericin B in the treatment of experimental cryptococcosis. J Infect Dis 1994; 170:1331-4.
72. Lutz JE, demons KV, Stevens DA. Enhancement of antifungal chemotherapy by interferon-gamma in experimental systemic cryptococcosis. J Antimicrob Chemother 2000; 46:437-42.
73. Clemons KV, Lutz JE, Stevens DA. Efficacy of recombinant gamma interferon for treatment of systemic cryptococcosis in SCID mice. Antimicrob Agents Chemother 2001; 45:686-9.
74. Pappas PG, Bustamante B, Ticona E, et al. Recombinant interferon-γ1β as adjunctive therapy for AIDS-related acute cryptococcal meningitis. J Infect Dis 2004; 189:2185-91.
75. Clemons KV, Darbonne WC, Curnutte JT, Sobel RA, Stevens DA. Experimental histoplasmosis in mice treated with anti-murine interferon-gamma antibody and in interferon-gamma gene knockout mice. Microbes Infect 2000; 2:997-1001.
76. Clemons KV, Lutz JE, Stevens DA. Efficacy of interferon-gamma and amphotericin B for the treatment of systemic murine histoplasmosis. Microbes Infect 2001; 3:3-10.
77. Cano LE, Kashino SS, Arruda C, et al. Protective role of gamma interferon in experimental pulmonary paracoccidioidomycosis. Infect Immun 1998; 66:800-6.
78. Kullberg BJ, van t'Wout JW, Hoogstraten C, von Furth R. Recombinant interferon-γ enhances resistance to acute disseminated Candida albicans infections in mice. J Infect Dis 1993; 168:436-43.
79. Zucker KE, Kamberi P, Sobel RA, et al. Temporal expression of inflammatory mediators in brain basilar artery vasculitis and cerebrospinal fluid of rabbits with coccidioidal meningitis. Clin Exp Immunol 2006; 143:458-66.
80. Ampel NM, Kramer LA, Kerekes KM, Johnson SM, Pappagianis D. Assessment of the human cellular immune response to T27K, a coccidioidal antigen preparation, by flow cytometry of whole blood. Med Mycol 2001; 39:315-20.
81. Ampel NM, Kramer LA, Li L, et al. In vitro whole-blood analysis of cellular immunity in patients with active coccidioidomycosis by using the antigen preparation T27K. Clin Diagn Lab Immunol 2002; 9:1039-43.
82. Corry DB, Ampel NM, Christian L, Locksley RM, Galgiani JN. Cytokine production by peripheral blood mononuclear cells in human coccidioidomycosis. J Infect Dis 1996; 174:440-3.
83. Brass C, Stevens DA. Maturity as a critical determinant of resistance to fungal infections: studies in murine blastomycosis. Infect Immun 1982; 36:387-95.
84. Ganer A, Brummer E, Stevens DA. Correlation of susceptibility of immature mice to fungal infection (blastomycosis) and effector cell function. Infect Immun 2000; 68:6833-9.
85. Kethineni N, Brummer E, Stevens DA. Susceptibility to pulmonary blastomycosis in young compared to adult mice: immune deficiencies in young mice. Med Mycol 2006; 44:51-6.
86. Clemons KV, Kamberi P, Chiller TM, et al. Effects of interferon-γ gene therapy in the murine central nervous system and concentrations in cerebrospinal fluid after intrathecal or intracerebral administration. Biotechnology 2005; 4:11-8.
87. Wolf SF, Sieburth D, Sypek J. Interleukin 12: a key modulator of immune function. Stem Cells 1994; 12:154-68.
88. Clemons KV, Brummer E, Stevens DA. Cytokine treatment of central nervous system infection: efficacy of interleukin-12 alone and synergy with conventional antifungal therapy in experimental cryptococcosis. Antimicrob Agents Chemother 1994; 38:460-4.
89. Zhou P, Sieve MC, Bennett J, et al. IL-12 prevents mortality in mice infected with Histoplasma capsulatum through induction of IFN-gamma. J Immunol 1995; 155:785-95.
90. Zhou P, Sieve MC, Tewari RP, Seder RA. Interleukin-12 modulates the protective immune response in SCID mice infected with Histoplasma capsulatum. Infect Immun 1997; 65:936-42.
91. Magee DM, Cox RA. Interleukin-12 regulation of host defenses against Coccidioides immitis. Infect Immun 1996; 64:3609-13.
92. Brummer E, Vinoda V, Stevens DA. IL-12 induction of resistance to pulmonary blastomycosis [abstract 406]. In: XV Congress of the International Society for Human and Animal Mycology (San Antonio, TX). International Society for Human and Animal Mycology, 2003:468.
93. Sechler JM, Malech HL, White CJ, Gallin JI. Recombinant human interferon-gamma reconstitutes defective phagocyte function in patients with chronic granulomatous disease of childhood. Proc Natl Acad Sci USA 1988; 85:4874-8.
94. Gallin JI. Interferon-gamma in the management of chronic granulomatous disease. Rev Infect Dis 1991; 13:973-8.
95. Rex JH, Bennett JE, Gallin JI, Malech HL, DeCarlo ES, Melnick DA. In vivo interferon-gamma therapy augments the in vitro ability of chronic granulomatous disease neutrophils to damage Aspergillus hyphae. J Infect Dis 1991; 163:849-52.
96. Kullberg BJ. Trends in immunotherapy of fungal infections. Eur J Clin Microbiol Infect Dis 1997; 16:51-5.
97. Kullberg Bf, Anaissie EJ. Cytokines as therapy for opportunistic fungal infections. Res Immunol 1998; 149:478-88.
98. Stevens DA, Domer JE, Ashman RB, Blackstock R, Brummer E. Immunomodulation in mycoses. J Med Vet Mycol 1994; 32(Suppl 1):253-65.
99. Stevens DA. Combination immunotherapy and antifungal chemotherapy. Clin Infect Dis 1998; 26:1266-9.
100. Stevens DA, Kullberg BJ, Brummer E, Casadevall A, Netea MG, Sugar AM. Combined treatment: antifungal drugs with antibodies, cytokines or drugs. Med Mycol 2000; 38(Suppl 1):305-15.
101. Clemons KV, Stevens DA. Immunomodulation of fungal infections: do immunomodulators have a role in treating mycoses? EOS Rivista di Immunologia e Immunofarmacologia 2002; 22:29-32.
102. Steinbach WJ, Stevens DA. Review of newer antifungal and immunomodulatory strategies for invasive aspergillosis. Clin Infect Dis 2003; 37(Suppl 3):S157-87.